Tag: AML

Find relevant news articles from other European projects, below:

CARAMBA  EURE-CART  CARAT Network ATECT PROCROP T2EVOLVE

Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


Targeted12

Zelenoleucel in Phase 2 Study of Patients With AML

The first patient with acute myeloid leukemia in a phase 2 trial of the MultiTAA-specific T cell, MT-401 followed stem-cell transplant has been dosed with the agent, according to a press release by Marker Therapeutics, Inc.

Visit website
Immunotherapy Web Featured Images 99

Magrolimab plus azacitidine in treatment-naïve AML

  Feb 03 2021 Tagged AML, mAbs

David Sallman, MD, Moffitt Cancer Center, Tampa, FL, discusses a Phase Ib trial (NCT03248479) of magrolimab, a novel anti-CD47 antibody, plus azacitidine in untreated acute myeloid leukemia (AML) patients unfit for intensive chemotherapy.

Visit website
Onclive8

Immunotherapy Inches Forward in Development of Myeloid Malignancies

Amer Zeidan, MD, MHS, discusses how survival for patients with acute myeloid leukemia and myelodysplastic syndrome remains poor, and although immunotherapy has been positioned as a holy grail, it would be preemptive to predict its future based on the number of small studies that have been performed to date.

Visit website
vjhemonic11

Effect of BMT status on decitabine plus ipilimumab in R/R MDS/AML

Jacqueline Garcia, MD, Dana-Farber Cancer Institute, Boston, MA, presents the safety and clinical activity data from a Phase I study (NCT02890329) of decitabine (DAC) plus ipilimumab (IPI) in patients with relapsed/refractory (R/R) myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) in the post bone marrow transplant (BMT) or treatment naïve setting.

Visit website
Immunotherapy Web Featured Images 80

Iodine apamistamab conditioning led to 100% bone marrow transplant rate and engr...

  Dec 29 2020 Tagged AML, mAbs

Treatment with iodine (131I) apamistamab (Iomab-B) conditioning led to a 100% bone marrow transplant rate and engraftment in patients with active relapsed/refractory acute myeloid leukemia who are older than 55 years old, according to results of a single ad hoc interim analysis of the phase 3 SIERRA study.

Visit website
vjhemonic16

SIERRA: Iomab-B for pre-HSCT AML

  Dec 14 2020 Tagged mAbs, AML

Sergio Giralt, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, discusses the prospective Phase III SIERRA trial (NCT02665065) of targeted radiotherapy with iomab-B, an anti-CD45 monoclonal antibody, in relapsed/refractory acute myeloid leukemia (AML).

Visit website
vjhemonic17

Current immune checkpoint inhibitor trials in AML/MDS

  Dec 07 2020 Tagged ICI, AML, MDS

Amer Zeidan, MBBS, MHS, Yale University School of Medicine and Yale Cancer Center, New Haven, CT, discusses several current trials of immune checkpoint inhibition in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) that were presented at ASH 2020.

Visit website
Immunotherapy Web Featured Images 46

ASH 2020 | Phase I trial of decitabine plus ipilimumab in R/R MDS & AML

Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of a Phase I trial (NCT02890329) of decitabine (DAC) in combination with ipilimumab (IPI) in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML), with or without prior allogeneic hematopoietic cell transplantation (allo-HCT).

Visit website
Immunotherapy Web Featured Images 33

iwCAR-T meeting 2020: featured sessions

  Nov 26 2020 Tagged CAR-T, NHL, ALL, AML, MM, CLL

During iwCAR-T 2020, some of the world’s leading clinical researchers shared their perspectives on how to place our evolving understanding in a clinical context and thereby optimize clinical care.

Visit website